Updated on 25 June 2014
Lupin is currently said to be scouting for companies in Japan, where it has established a presence in the complex injectable space
Singapore: In a bid to expand its product portfolio, India's fourth largest domestic drug maker (in terms of revenue) is planning some major acquisitions.
The company has said in a news statement that it plans to enter new geographies and expand its portfolio simultaneously. Lupin is currently said to be scouting for companies in Japan, where it has established a presence in the complex injectable space.
"We have identified a few growth areas. One of them is to have presence in markets such as Russia, China, Korea, Turkey and Brazil," Mr Nilesh Gupta, managing director, Lupin said in the statement.
The company entered Mexico recently through an acquisition and is said to be trying to build a presence in Brazil for 5-7 years now.
"The Latin American market is a profitable market, much bigger in size than the Indian market and is growing faster than India. On long-term perspective, it is important for us to be in markets like these," Mr Gupta pointed out.
Further, the company revealed that a strategic move that they are contemplating is acquisition of certain Indian companies too. This, they added would help them enter newer regions and therapeutic areas.